Clinical Trial Applications - Stopped: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Stopped | |
|---|---|---|---|---|---|
51. |
ECCT/19/12/02 | VPM1002 Phase III PoI A multicenter, Phase III double blind, randomized active controlled study to evaluate efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in newborn infants. |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI-CRDR Nairobi (Nairobi City county) 2. KEMRI-CRDR Siaya (Siaya county) |
Not recorded |
View |
52. |
ECCT/25/03/01 | MK-5684_MSD (mCRPC) A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) |
Principal Investigator(s) 1. PROF MANSOOR NOORALI SALEH Site(s) in Kenya AGA KHAN UNIVERSITY HOSPITAL NAIROBI |
Not recorded |
View |
53. |
ECCT/21/12/04 | FAST Study Assessments of the EFficacy, the onset-of-Action and the Safety of Tot'héma® in adults with moderate iron deficiency anaemia |
Principal Investigator(s) 1. Dr. Francis Xavier Otieno Odawa Site(s) in Kenya 1. MOI University Teaching and Referral Hospital (Nandi county) 2. UNIM Research and Training Centre (Kisumu county) 3. Kenyatta National Hospital (Nairobi City county) |
Not recorded |
View |
54. |
ECCT/21/06/09 | STEADFAST STUDY A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients ≥ 16 years with chronic kidney disease due to sickle cell nephropathy (STEADFAST) |
Principal Investigator(s) 1. Professor Benhards Ragama Ogutu Ogutu 2. Professor Frederick Asirwa Chite Chite 3. Dr Doreen Mutua Mutua Site(s) in Kenya 1. Site 1300 - CREATES Strathmore University (Nairobi City county) 2. Site 1301 - International Cancer Institute (Uasin Gishu county) 3. Site 1302 - Gertrudes\'s Childrens Hospital (Nairobi City county) |
Not recorded |
View |
55. |
ECCT/10/09/03 | A0661201 A0661201 AN OPEN LABEL, NON-COMPARATIVE STUDY TO EVALUATE PARASITOLOGICAL CLEARANCE RATES AND PHARMACOKINETICS OF AZITHROMYCIN AND CHLOROQUINE FOLLOWING ADMINISTRATION OF A FIXED DOSE COMBINATION OF AZITHROMYCIN AND CHLOROQUINE (AZCQ) IN ASYMPTOMATIC PREGNANT WOMEN WITH PLASMODIUMFALCIPARUM PARASITEMIA IN SUB-SAHARAN AFRICA |
Principal Investigator(s) 1. Joshua Kimani Site(s) in Kenya University of Nairobi Institute of Tropical and Infectious Diseases Siaya District Hospital |
Not recorded |
View |
56. |
ECCT/17/05/03 | TDF IVR-002 Study Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002) |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya Partners in Health Research & Development (Thika Partners Clinical Trial Site) |
Not recorded |
View |
57. |
ECCT/17/05/01 | Multicenter Study of the Accuracy of the BD MAXâ„¢MDR-TB Assay Multicenter Study of the Accuracy of the BD MAX™MDR-TB Assay for Detection of M. tuberculosis Complex and Mutations Associated with Resistance to Rifampin or Isoniazid |
Principal Investigator(s) 1. SAMUEL GURRION OUMA Site(s) in Kenya KENYA MEDICAL RESEARCH INSTITIUTE |
Not recorded |
View |
58. |
ECCT/17/09/03 | A5354 Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses |
Principal Investigator(s) 1. Deborah Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Clinical Research Centre |
Not recorded |
View |
59. |
ECCT/21/12/02 | The WHO ACTION Trial ACTION III: A multi-country, multi-centre, three-arm, parallel group, double-blind, placebo-controlled, randomized trial of two doses of antenatal corticosteroids for women with a high probability of birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes |
Principal Investigator(s) 1. Frederick Namenya Were 2. John Kinuthia 3. Zahida Parveen Qureshi Site(s) in Kenya 1. Coast General Teaching and Referral Hospital (Mombasa county) 2. Thika Level 5 Hospital (Kiambu county) 3. Nakuru Level 5 Hospital (Nakuru county) |
Not recorded |
View |
60. |
ECCT/19/03/02 | PREVENT TD A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD) |
Principal Investigator(s) 1. Flynn Alexander Site(s) in Kenya Nyati Barracks, British Army Training Unit, Kenya |
Not recorded |
View |